69 related articles for article (PubMed ID: 9834230)
1. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells.
Bradley M; Zeytun A; Rafi-Janajreh A; Nagarkatti PS; Nagarkatti M
Blood; 1998 Dec; 92(11):4248-55. PubMed ID: 9834230
[TBL] [Abstract][Full Text] [Related]
2. Killing of Fas ligand-resistant renal carcioma cells by interleukin-2- and BCG-activated effector cells.
Brandau S; Suttmann H; Flad HD; Jocham D; Böhle A
Cancer Immunol Immunother; 2000 Sep; 49(7):369-76. PubMed ID: 10999463
[TBL] [Abstract][Full Text] [Related]
3. Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.
Rodolfo M; Salvi C; Parmiani G
Cancer Immunol Immunother; 1989; 28(2):136-42. PubMed ID: 2783888
[TBL] [Abstract][Full Text] [Related]
4. Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.
Baxevanis CN; Gritzapis AD; Spanakos G; Tsitsilonis OE; Papamichail M
Cancer Immunol Immunother; 1995 Jun; 40(6):410-8. PubMed ID: 7543022
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous exposure to interleukin-18 and interleukin-10 in vitro synergistically augments murine spleen natural killer cell activity.
Micallef MJ; Tanimoto T; Torigoe K; Nishida Y; Kohno K; Ikegami H; Kurimoto M
Cancer Immunol Immunother; 1999; 48(2-3):109-17. PubMed ID: 10414464
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.
Nagarkatti M; Nagarkatti PS; Kaplan AM
Cancer Immunol Immunother; 1988; 27(1):38-46. PubMed ID: 3260820
[TBL] [Abstract][Full Text] [Related]
7. Induction of lymphokine-activated killer activity in mice by prothymosin alpha.
Baxevanis CN; Gritzapis AD; Dedoussis GV; Papadopoulos NG; Tsolas O; Papamichail M
Cancer Immunol Immunother; 1994 Apr; 38(4):281-6. PubMed ID: 8168124
[TBL] [Abstract][Full Text] [Related]
8. In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models.
Eggermont AM; Sugarbaker PH; Marquet RL; Jeekel J
Cancer Immunol Immunother; 1988; 26(1):23-30. PubMed ID: 3257900
[TBL] [Abstract][Full Text] [Related]
9. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.
Fukuta K; Sone S; Kitahara M; Okada M; Ogura T
Jpn J Cancer Res; 1989 Jun; 80(6):562-7. PubMed ID: 2503476
[TBL] [Abstract][Full Text] [Related]
11. The role of interleukin-2 in regulating the sensitivity of natural killer cells for Fas-mediated apoptosis.
Haux J; Johnsen AC; Steinkjer B; Egeberg K; Sundan A; Espevik T
Cancer Immunol Immunother; 1999; 48(2-3):139-46. PubMed ID: 10414468
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 and interleukin-7 augment the cytolytic activity and expand the antitumor killing spectrum of alpha CD3-induced activated killer cells: potential use in the immunotherapy of non-immunogenic tumors.
Ting CC; Wang J; Yang Y
Cancer Immunol Immunother; 1996 Dec; 43(5):283-92. PubMed ID: 9024505
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor activity of interleukin-2 and cimetidine against syngeneic murine tumor.
Nakajima I; Chu TM
Cancer Immunol Immunother; 1991; 33(1):9-14. PubMed ID: 2021961
[TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of lymphokine (IL-2)-activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases.
Yamasaki K; Sone S; Yamashita T; Ogura T
Cancer Immunol Immunother; 1989; 29(2):87-92. PubMed ID: 2785852
[TBL] [Abstract][Full Text] [Related]
15. Effects of phenytoin on cell-mediated immunity.
Okamoto Y; Shimizu K; Tamura K; Miyao Y; Yamada M; Tsuda N; Matsui Y; Mogami H
Cancer Immunol Immunother; 1988; 26(2):176-9. PubMed ID: 3258793
[TBL] [Abstract][Full Text] [Related]
16. Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy.
Navarrete-Galvan L; Guglielmo M; Cruz Amaya J; Smith-Gagen J; Lombardi VC; Merica R; Hudig D
J Transl Med; 2022 Apr; 20(1):151. PubMed ID: 35366943
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-150 regulates the cytotoxicity of natural killers by targeting perforin-1.
Kim N; Kim M; Yun S; Doh J; Greenberg PD; Kim TD; Choi I
J Allergy Clin Immunol; 2014 Jul; 134(1):195-203. PubMed ID: 24698324
[TBL] [Abstract][Full Text] [Related]
18. Characterizing the anti-tumor function of adoptively transferred NK cells in vivo.
Pegram HJ; Haynes NM; Smyth MJ; Kershaw MH; Darcy PK
Cancer Immunol Immunother; 2010 Aug; 59(8):1235-46. PubMed ID: 20376439
[TBL] [Abstract][Full Text] [Related]
19. Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength.
Fiszer-Maliszewska L; Den Otter W; Mordarski M
Cancer Immunol Immunother; 1999 Feb; 47(6):307-14. PubMed ID: 10203060
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression.
Masztalerz A; Van Rooijen N; Den Otter W; Everse LA
Cancer Immunol Immunother; 2003 Apr; 52(4):235-42. PubMed ID: 12669248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
